

FOI 1594

13<sup>th</sup> April 2023

## **FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

### **Question 1:**

How many patients were treated in February 2023 (or latest available month) by the Respiratory Medicine department with the following drugs:

- Benralizumab (Fasenra)
- Dupilumab (Dupixent)
- Omalizumab (Xolair)
- Reslizumab (Cinqaero)
- Mepolizumab (Nucala)
- Tezepelumab (Tezspire)

### **Answer 1:**

• Benralizumab (Fasenra)	0
• Dupilumab (Dupixent)	0
• Omalizumab (Xolair)	0
• Reslizumab (Cinqaero)	0
• Mepolizumab (Nucala)	0
• Tezepelumab (Tezspire)	0